Triple-negative breast cancer trials in China

In China 134 Also abroad 425

134 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Where
Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Linhai, Linyi, Nanjing, Nanning, Neijiang, Taiyuan, Ürümqi, Wuhan, Xiamen, Xi'an, Xiangyang, Xuzhou, Zhengzhou
Age
18 years and over
People
1,000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00
Phase 3Taking people
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Where
Beijing, Changchun, Changsha, Deyang, Guangzhou, Haerbin, Hangzhou, Hefei, Jiangmen, Jinan, Kunming, Linyi, Liuzhou, Nanchang, Nanjing, Nanning, Neijiang, Shanghai, Ürümqi, Wuhan, Xiamen, Xi'an, Xingtai, Zhengzhou
Age
18 years and over
People
2,400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00
Phase 3Taking people
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
Where
Shanghai
Age
18 years to 70 years
People
424
Run by
Fudan University
See details and how to joinNCT05999149
Phase 2Taking people
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Where
Shanghai
Age
18 years to 70 years
People
39
Run by
Fudan University
See details and how to joinNCT06793332
Phase 1/2Taking people
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Where
Beijing, Hubei, Hunan
Age
18 years to 75 years
People
42
Run by
Shenzhen Majory Biotechnology Co., Ltd.
See details and how to joinNCT07208149
Phase 2Taking people
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
Where
Baoding, Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Jining, Lanzhou, Mianyang, Nanchang, Nanjing, Qingdao, Shenyang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou
Age
18 years to 70 years
People
184
Run by
Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT07876557
Phase 1/2Taking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Guangdong, Hangzhou, Henan, Hubei, Nanchang, Shanghai, Shanxi, Shengyang, Tianjin
Age
18 years and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Beijing, Guangzhou, Shanghai
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Taking people
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
Where
Jinan
Age
18 years to 70 years
People
72
Run by
Shandong Cancer Hospital and Institute
See details and how to joinNCT06802757
Phase 3Taking people
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Where
Changde, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanchang, Nanjing, Neijiang, Shanghai, Taiyuan, Wuhan, Xi'an, Yongzhou, Zhengzhou
Age
18 years and over
People
558 worldwide
Run by
BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00
Phase 2Taking people
SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
Where
Shanghai
Age
18 years to 75 years
People
120
Run by
Tianjin ConjuStar Biologics Co., Ltd.
See details and how to joinNCT07080619
Phase 2Taking people
Pucotenlimab and Anlotinib in Combination With Chemotherapy
Where
Hangzhou
Age
18 years and over
People
34
Run by
Zhejiang Cancer Hospital
See details and how to joinNCT07896668
Phase 2Taking people
Reverse Triple Negative Immune Resistant Breast Cancer
Where
Shanghai
Age
18 years to 70 years
People
90
Run by
Fudan University
See details and how to joinNCT05076682
Phase 2Taking people
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Where
Guangzhou
Age
18 years to 70 years
People
430
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06992336
No phaseTaking people
Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer
Where
Fuzhou, Ningde, Quanzhou, Sanming
Age
18 years and over
People
120
Run by
Fujian Cancer Hospital
See details and how to joinNCT07880600
Phase 3Taking people
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
Where
Shanghai
Age
18 years to 75 years
People
436
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07729956
Phase 3Taking people
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
Where
Sichuan
Age
18 years to 65 years
People
318
Run by
West China Hospital
See details and how to joinNCT06627712
Phase 2Taking people
Capecitabine in Low Risk Triple Negative Breast Cancer
Where
Shanghai
Age
18 years and over
People
198
Run by
Fudan University
See details and how to joinNCT06787339
Phase 2Taking people
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Where
Tianjin
Age
18 years to 75 years
People
40
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07372079
Phase 3Taking people
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Where
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanjing, Nanning, Shandong, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Xi'an, Xintai, Xuzhou, Zhanjiang, Zhengzhou
Age
18 years and over
People
625 worldwide
Run by
AstraZeneca
See details and how to joinNCT06103864
Phase 2Not yet taking people in China
Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
Where
Shanghai
Age
18 years to 70 years
People
46
Run by
Fudan University
See details and how to joinNCT07419880
Phase 2Taking people
Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
Where
Shanghai
Age
18 years to 70 years
People
58
Run by
Fudan University
See details and how to joinNCT07638852
Phase 3Taking people
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
Where
Beijing
Age
18 years to 75 years
People
1,000
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07679360
Phase 2Taking people
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
Where
Bengbu
Age
18 years to 80 years
People
128
Run by
The First Affiliated Hospital of Bengbu Medical University
See details and how to joinNCT05192798
Phase 2Taking people
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Where
Shanghai
Age
18 years and over
People
160
Run by
Fudan University
See details and how to joinNCT06649331